Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 30th, there was short interest totaling 7,209 shares, a growth of 74.6% from the September 15th total of 4,130 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average daily volume of 7,501 shares, the days-to-cover ratio is presently 1.0 days.
Fidelity Disruptive Medicine ETF Stock Performance
Shares of NASDAQ FMED traded down $0.97 during midday trading on Friday, reaching $30.27. 17,547 shares of the company’s stock were exchanged, compared to its average volume of 10,454. Fidelity Disruptive Medicine ETF has a 52-week low of $23.48 and a 52-week high of $32.99. The business’s fifty day moving average price is $31.53 and its two-hundred day moving average price is $28.18. The stock has a market capitalization of $48.42 million, a PE ratio of 41.33 and a beta of 0.76.
Hedge Funds Weigh In On Fidelity Disruptive Medicine ETF
An institutional investor recently bought a new position in Fidelity Disruptive Medicine ETF stock. Citadel Advisors LLC bought a new stake in shares of Fidelity Disruptive Medicine ETF (NASDAQ:FMED – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 9,896 shares of the company’s stock, valued at approximately $282,000. Citadel Advisors LLC owned about 0.62% of Fidelity Disruptive Medicine ETF at the end of the most recent quarter.
About Fidelity Disruptive Medicine ETF
The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.
Featured Stories
- Five stocks we like better than Fidelity Disruptive Medicine ETF
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Fidelity Disruptive Medicine ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fidelity Disruptive Medicine ETF and related companies with MarketBeat.com's FREE daily email newsletter.
